Author:
Xu Jianming,Gao Emei,Han Yu,Zhang Yang,Li Suxia,Liu Xiaoqing,Li Zhiqiang,Paradiso Angelo
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small cell lung cancer. Clin Lung Cancer, 2004, 6: 154–161.
2. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal, 2001, 2: 4–11.
3. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol, 2002, 29: 3–9.
4. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 2002, 62: 5749–5754.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol, 2003, 21: 2237–2246.